Satellite Bio Wins FDA IND Clearance for SB-101, Marking Transition to Clinical-Stage Company

Satellite Biosciences, Inc. (Satellite Bio) announced that the US Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for SB-101, an investigational cell therapy for the treatment of urea cycle disorders (UCDs).¹ The clearance marks the company's transition from a preclinical to a clinical-stage biotechnology company.¹ Satellite Bio plans to initiate a phase 1/2 clinical trial evaluating the safety, tolerability, pharmacodynamics, and preliminary efficacy of SB-101 in infants with severe early-onset UCDs later in 2026.¹

How does SB-101 work?

SB-101 is a first-in-class, off-the-shelf liver cell therapy built on Satellite Bio's platform for delivering healthy hepatocytes to receptive sites in the body, where the cells can engraft and restore metabolic function.¹ The therapy is manufactured in advance and cryopreserved, intended to provide a ready-to-use treatment option for infants who require urgent intervention rather than one built around a patient-specific manufacturing timeline.¹ The liver performs more than 500 vital functions, including detoxifying harmful substances such as ammonia, processing nutrients, and producing essential blood proteins, and SB-101 is designed to restore this detoxification capacity in patients whose own liver cells cannot adequately perform it.¹

Why does this indication matter clinically?

Urea cycle disorders are rare inherited diseases in which the liver cannot effectively convert toxic ammonia into urea for elimination from the body.¹ As ammonia accumulates, patients can rapidly develop irreversible brain injury, seizures, encephalopathy, coma, and multi-organ failure.¹ Current treatment options remain inadequate: mortality among UCD patients exceeds 25%, cognitive impairment affects approximately half of surviving patients, and no curative treatment is available during the first weeks of life, when the risk of a life-threatening hyperammonemic crisis is highest.¹ This aligns with a broader push in pediatric rare disease therapeutics toward one-time or off-the-shelf interventions for ultra-rare inherited conditions where traditional standard-of-care options remain limited or unavailable in early infancy.

What did company leadership say?

Tom Lowery, PhD, president and chief executive officer of Satellite Bio, said, "We are thrilled to transition to clinical-stage company with this cleared IND."¹ Satellite Bio has said its approach aims to harness living cells as medicines to address severe liver disease at its source, and that while SB-101 is initially focused on UCDs, the underlying platform is designed to support delivery of healthy hepatocytes across a broader range of liver diseases.¹

What happens next?

Satellite Bio expects to initiate its phase 1/2 clinical trial of SB-101 in infants with severe early-onset UCDs in late 2026.¹ The IND clearance follows the FDA's Rare Pediatric Disease designation granted to SB-101 earlier in 2026, which could make the company eligible for a Priority Review Voucher if SB-101 is ultimately approved.² Satellite Bio's broader pipeline includes additional candidates designed to improve liver function in other pediatric liver diseases and in adult patients with chronic liver disease.¹

References

1. Satellite Bio announces FDA clearance of IND application for SB-101 for the treatment of urea cycle disorders (UCDs) marking its transition to a clinical-stage biotechnology company. News release. Satellite Biosciences, Inc; August 4, 2026. Accessed August 4, 2026.
2. Satellite Bio announces FDA Rare Pediatric Disease designation for SB-101 for the treatment of urea cycle disorders (UCDs). News release. Satellite Biosciences, Inc; May 4, 2026. Accessed August 4, 2026.